Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedul...

BACKGROUND In an earlier study, intravenous (i.v.) ibandronate 6 mg administered every 3-4 weeks had a similarly good renal safety profile whether infused over 15 or 60 min in women with breast cancer and bone metastases. This current study focuses on the renal safety of the extended use of ibandronate. PATIENTS AND METHODS Patients completing the original study could choose to enter a follow...

PURPOSE Bone metastasis invariably increases morbidity and mortality. This study compares the effects of ibandronate and paclitaxel on bone structure and its mechanical properties and biochemical turnover in resorption markers using an immunocompetent Walker 256-Sprague-Dawley model, which was subjected to tumor-induced osteolysis. MATERIALS AND METHODS Seventy rats were divided equally into ...

Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experienced GI irritation with bisphosphonate (BP) use. In PRIOR, women who had discontinued daily or w...

For defining the optimal regimen of a treatment of osteoporosis with an intravenous bisphosphonate one needs to know the duration of action of a single dose of the given drug. This allows us to establish the frequency by which a given dose has to be administered for obtaining a sufficient suppression of bone resorption over a longer period. In this study 1 and 2 mg Ibandronate were given as a s...

Background: CDSO is a condition affecting predominantly the mandible and long bones of young females, characterised by episodes of intractable pain on a background of chronic discomfort. The aetiology is unknown, but the bone sclerosis is associated with abnormal osteoblast and osteoclast function. Methods: We report 3 cases in which symptoms and biochemical markers responded to treatment with ...

Correspondence: Jean-Jacques Body, M.D., Ph.D., Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Héger-Bordet, 1000 Brussels, Belgium. Telephone: 32-2-541-3303; Fax: 32-2-541-3311; e-mail: [email protected] Received August 1, 2005; accepted for publication August 29, 2005. ©AlphaMed Press 1083-7159/2005/$12.00/0 Bisphosphonates are routinely used for managing metastatic bone disease....

Osteoporosis is a chronic condition that generally requires long-term therapy for fracture risk reduction to become apparent. Although the bisphosphonates have made a major contribution to how clinicians manage osteoporosis, compliance with therapy has generally been less in the real-world setting than seen in clinical trials. Less-frequently administered dosage regimens or nonoral routes may e...

Abstract Background Lumbar spinal stenosis (LSS) can cause various neurological symptoms and reduce the daily activity of patients. Many studies have shown that free physical activities exercise improve bone mineral density (BMD) in patients with osteoporosis. However, effect LSS on BMD has not been reported. The purpose this study was to investigate effects treated ibandronate for newly diagno...

The majority of breast cancers occur in women over the age 65, but older cancer patients are largely underrepresented clinical trials. We investigated effect adding capecitabine to adjuvant treatment with ibandronate elderly patients. multicenter phase III ICE trial enrolled ≥65 years early node-positive/high-risk node-negative and a Charlson Comorbidity Index (CCI) ≤2. Patients were randomized...